Science news

<<  return


The IMPROVE-IT study, the large cardiovascular-outcomes trial that showed a clinical benefit to adding to statin therapy in post–acute coronary syndrome (ACS) patients, is now published. The IMPROVE-IT study showed that adding ezetimibe 10 mg to simvastatin 40 mg resulted in an absolute 2.0% reduction in the primary end point over 7 years when compared with ACS patients who received simvastatin 40 mg alone.

Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; DOI:101056.NEJMoa1410489. Available at:

Jarcho JA, Keaney JF. Proof that lower is better—LDL cholesterol and IMPROVE-IT. N Engl J Med 2015. Published online June 3, 2015. Available at: